Behind the headlines: Therapeutics development from academic lab, to spin out and exit
Tracks
Track 2
| Friday, November 1, 2024 |
| 11:45 AM - 12:30 PM |
Details
The cost, timeline and risk associated with bringing therapeutic products to market are often quoted. At figures of around US$2B per drug (including failures) and more than 10 years to get to market, the odds and resources required appear insurmountable. This panel will discuss how they are “getting it done”, drawing on their experiences across the therapeutics development continuum from academic spin out, to hitting key value inflection points, and successful exit.
Speaker
Dr Janine Bilsborough
Director, Inflammatory Bowel Disease Drug Discovery and Development
Cedars-Sinai, Medicine
Panellist
Dr Martine Keenan
Chief Innovation Officer, SYNthesis; Research and Chief Operating Officer
Synthesis Research
Panellist
Dr. Anne-Laure Puaux
Head, Business Development and CEO WEHI Ventures
WEHI
Chair
